NCT00268385 2026-03-18
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT03426891 2025-10-06
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00838929 2025-05-04
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Thomas Jefferson University
Phase 1 Completed
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01342757 2018-01-29
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase NA Completed
NCT00946673 2017-10-06
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
Phase 1 Completed
NCT01738646 2017-03-06
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Duke University
Phase 2 Completed
NCT00238303 2014-05-23
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00641706 2014-05-14
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT01600742 2014-01-09
Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
National Taiwan University Hospital
Phase 2 Terminated
NCT00939991 2013-06-24
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Duke University
Phase 1/2 Completed